Literature DB >> 24862987

Whole genome identification of C. trachomatis immunodominant antigens after genital tract infections and effect of antibiotic treatment of pigtailed macaques.

Dorothy L Patton1, Andy Teng2, Arlo Randall2, Xiaowu Liang2, Philip L Felgner2, Luis M de la Maza3.   

Abstract

The cervix and/or fallopian tubes of pigtailed macaques were experimentally infected with Chlamydia trachomatis. Their sera were collected at varying time points and screened for identification of immunodominant antigens using a whole-genome protein microarray. The effect of doxycycline treatment on the antibody response generated in these macaques was also investigated. Twenty-five female macaques were infected with C. trachomatis serovars D or E in the cervix and/or fallopian tubes. Bloods were collected at baseline and at various intervals after challenge. Serum samples were tested for antibodies using a C. trachomatis serovar D protein microarray. Twenty chlamydial antigens reacted with sera from at least 68% (17/25) of the macaques. In addition to some well-known chlamydial antigens, nine different proteins, not previously recognized as immunodominant, including four hypothetical proteins (CT005, CT066, CT360 and CT578), were identified. Monkeys infected in the fallopian tubes developed a more robust antibody response than animals inoculated in the cervix. Treatment with doxycycline significantly decreased Chlamydia-specific antibody levels. In summary, using protein microarray serum samples from experimentally infected pigtailed macaques were screened for immunodominant chlamydial antigens. These antigens can now be tested in animal models for their ability to protect and as markers of disease progression. BIOLOGICAL SIGNIFICANCE: This is the first time that Chlamydia trachomatis immunodominant antigens have been identified in pigtailed macaques following a uterine cervix or a fallopian tubes infection. These immunodominant antigens can now be used to vaccinate non-human primates and determine their ability to protect against a C. trachomatis genital infection. Proteins that are protective can subsequently be tested in humans. Amongst the immunodominant antigens some were predominantly recognized by sera from macaques inoculated in the fallopian tubes rather than in the cervix and therefore, may be markers for upper genital tract pathology. In addition, treatment with doxycycline following infection significantly decreased Chlamydia-specific antibody levels. This information can be used to evaluate the efficacy of antibiotic treatment and potentially susceptibility to reinfection.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibiotics; Antibody response; Chlamydia trachomatis; Macaca nemestrina; Pigtailed macaques; Protein microarrays

Mesh:

Substances:

Year:  2014        PMID: 24862987      PMCID: PMC4112733          DOI: 10.1016/j.jprot.2014.05.009

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  43 in total

Review 1.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Proteome-wide analysis of the serological response to vaccinia and smallpox.

Authors:  D Huw Davies; Douglas M Molina; Jens Wrammert; Joe Miller; Siddiqua Hirst; Yunxiang Mu; Jozelyn Pablo; Berkay Unal; Rie Nakajima-Sasaki; Xiaowu Liang; Shane Crotty; Kevin L Karem; Inger K Damon; Rafi Ahmed; Luis Villarreal; Philip L Felgner
Journal:  Proteomics       Date:  2007-05       Impact factor: 3.984

3.  A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans.

Authors:  Jie Wang; Yingqian Zhang; Chunxue Lu; Lei Lei; Ping Yu; Guangming Zhong
Journal:  J Immunol       Date:  2010-06-25       Impact factor: 5.422

4.  The effect of doxycycline treatment on the development of protective immunity in a murine model of chlamydial genital infection.

Authors:  H Su; R Morrison; R Messer; W Whitmire; S Hughes; H D Caldwell
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

5.  Is the increase in notifications of Chlamydia trachomatis infections in Sweden the result of changes in prevalence, sampling frequency or diagnostic methods?

Authors:  Hannelore Götz; Johan Lindback; Torvald Ripa; Malin Arneborn; Kristina Ramsted; Karl Ekdahl
Journal:  Scand J Infect Dis       Date:  2002

6.  CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection.

Authors:  Christina M Farris; Sandra G Morrison; Richard P Morrison
Journal:  Infect Immun       Date:  2010-07-26       Impact factor: 3.441

7.  Prediction of the membrane-spanning beta-strands of the major outer membrane protein of Chlamydia.

Authors:  María José Rodríguez-Marañón; Robin M Bush; Ellena M Peterson; Tilman Schirmer; Luis M de la Maza
Journal:  Protein Sci       Date:  2002-07       Impact factor: 6.725

8.  Host response to primary Chlamydia trachomatis infection of the fallopian tube in pig-tailed monkeys.

Authors:  D L Patton; S A Halbert; C C Kuo; S P Wang; K K Holmes
Journal:  Fertil Steril       Date:  1983-12       Impact factor: 7.329

9.  Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays.

Authors:  Douglas M Molina; Sukumar Pal; Mathew A Kayala; Andy Teng; Paul J Kim; Pierre Baldi; Philip L Felgner; Xiaowu Liang; Luis M de la Maza
Journal:  Vaccine       Date:  2009-12-29       Impact factor: 3.641

10.  Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis.

Authors:  Guifeng Sun; Sukumar Pal; Annahita K Sarcon; Soyoun Kim; Etsuko Sugawara; Hiroshi Nikaido; Melanie J Cocco; Ellena M Peterson; Luis M de la Maza
Journal:  J Bacteriol       Date:  2007-06-29       Impact factor: 3.490

View more
  8 in total

1.  Survey of major histocompatibility complex class II diversity in pig-tailed macaques.

Authors:  Julie A Karl; Katelyn E Heimbruch; Claire E Vriezen; Cassandra J Mironczuk; Dawn M Dudley; Roger W Wiseman; David H O'Connor
Journal:  Immunogenetics       Date:  2014-08-17       Impact factor: 2.846

2.  A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge.

Authors:  Sukumar Pal; Olga V Tatarenkova; Luis M de la Maza
Journal:  Immunology       Date:  2015-10-01       Impact factor: 7.397

Review 3.  A re-evaluation of the role of B cells in protective immunity to Chlamydia infection.

Authors:  Lin-Xi Li; Stephen J McSorley
Journal:  Immunol Lett       Date:  2015-02-20       Impact factor: 3.685

Review 4.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

Review 5.  A systems biology approach for diagnostic and vaccine antigen discovery in tropical infectious diseases.

Authors:  Li Liang; Philip L Felgner
Journal:  Curr Opin Infect Dis       Date:  2015-10       Impact factor: 4.915

6.  Eukaryotic Cell Permeabilisation to Identify New Putative Chlamydial Type III Secretion System Effectors Secreted within Host Cell Cytoplasm.

Authors:  Carole Kebbi-Beghdadi; Ludovic Pilloux; Virginie Martin; Gilbert Greub
Journal:  Microorganisms       Date:  2020-03-03

Review 7.  Mesenchymal Stem-Cell Derived Exosome Therapy as a Potential Future Approach for Treatment of Male Infertility Caused by Chlamydia Infection.

Authors:  Mahin Izadi; Laleh Dehghan Marvast; Mohammad Ebrahim Rezvani; Marzieh Zohrabi; Ali Aliabadi; Seyed Alireza Mousavi; Behrouz Aflatoonian
Journal:  Front Microbiol       Date:  2022-01-13       Impact factor: 5.640

8.  Genome-wide profiling of humoral immunity and pathogen genes under selection identifies immune evasion tactics of Chlamydia trachomatis during ocular infection.

Authors:  Harry Pickering; Andy Teng; Nkoyo Faal; Hassan Joof; Pateh Makalo; Eunice Cassama; Meno Nabicassa; Anna R Last; Sarah E Burr; Sarah L Rowland-Jones; Nicholas R Thomson; Chrissy H Roberts; David C W Mabey; Robin L Bailey; Richard D Hayward; Luis M de la Maza; Martin J Holland
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.